PMCB (PharmaCyte Biotech) Revenue: $0.00 Mil (TTM As of Jan. 2026)


PMCB PharmaCyte Biotech Inc PMCB
30 GF Score
Price $0.73
! 2 Warning Signs
View Full Analysis

What is PharmaCyte Biotech Revenue?

PharmaCyte Biotech PMCB +1.20% 30 Revenue is $0.00 Mil as of Jan. 2026. GuruFocus rates PMCB with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

PharmaCyte Biotech's revenue for the three months ended in Jan. 2026 was $0.00 Mil. Its revenue for the trailing twelve months (TTM) ended in Jan. 2026 was $0.00 Mil. PharmaCyte Biotech's Revenue per Share for the three months ended in Jan. 2026 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Jan. 2026 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, PharmaCyte Biotech's highest 3-Year average Revenue per Share Growth Rate was 596.90% per year. The lowest was -68.50% per year. And the median was -50.60% per year.


PharmaCyte Biotech  (NAS:PMCB) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


PharmaCyte Biotech Revenue Related Terms


PharmaCyte Biotech Revenue Historical Data

* Premium members only.

The historical data trend for PharmaCyte Biotech's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaCyte Biotech Revenue Chart

PharmaCyte Biotech Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PharmaCyte Biotech Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PMCB vs ERNA, SYBX, ASBP: Revenue Comparison

For the Biotechnology subindustry, PharmaCyte Biotech's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PharmaCyte Biotech Revenue vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PharmaCyte Biotech's Revenue distribution charts can be found below:

* The bar in red indicates where PharmaCyte Biotech's Revenue falls into.


PMCB
30GF Score
PharmaCyte Biotech Inc PMCB
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PharmaCyte Biotech Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of $0.00 Mil mean?
PharmaCyte Biotech (PMCB) has a Revenue of $0.00 Mil as of Jan. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on PharmaCyte Biotech and its competitors.
Is PharmaCyte Biotech's Revenue too high?
PharmaCyte Biotech's current Revenue is $0.00 Mil. Overall, PharmaCyte Biotech has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does PharmaCyte Biotech's Revenue compare to ERNA and SYBX?
PharmaCyte Biotech's Revenue of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on PharmaCyte Biotech and its competitors. PharmaCyte Biotech's current Revenue is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCyte Biotech stock overvalued right now?
PharmaCyte Biotech (PMCB) has a current Revenue of $0.00 Mil. The current Revenue is $0.00 Mil. PharmaCyte Biotech's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For PharmaCyte Biotech (PMCB), the current Revenue is $0.00 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PharmaCyte Biotech Business Description

Address 3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV, USA, 89169
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
30GF Score

Get the complete analysis for PMCB

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.73
Price